Egide (ALGID) H1 2026 earnings summary

Executive summary

• H1 2026 revenue was €15.20m, down 2.4% reported but up 0.7% at constant exchange rates; excluding Santier, revenue rose 2% to €13.8m.

• Net loss narrowed to €0.87m from €2.04m; excluding Santier, EBITDA was €1.25m and net income €0.77m.

Financial highlights

• Consolidated EBITDA improved to -€0.08m from -€0.21m; operating loss narrowed to €0.67m from €1.39m.

• Excluding Santier, operating profit was €0.79m versus a €0.55m loss; net profit was €0.77m versus a €1.17m loss.

• Net financial expense narrowed to €0.10m from €0.73m, including a €0.14m reversal of foreign-exchange loss provisions.

• Lower consumed purchases (€5.51m vs €6.19m), personnel costs (€6.65m vs €7.13m) and external costs (€2.44m vs €2.64m) supported the operating-result improvement.

Outlook and guidance

• French operations are expected to grow in FY 2026 versus 2025, subject to continued Bollène operating-capacity recovery; the strategic-market order book is described as solid.

• H2 North American performance depends on customer-program delivery timing, backlog conversion, and Cambridge’s capacity and resource ramp-up.

• Santier assembly transfers to Cambridge are subject to qualification and are expected to contribute progressively from 2027; clients representing ~55% of Santier’s 2025 revenue approved the transfer in principle.